Efficacy of 8 Weeks Versus 12 Weeks of Elbasvir/Grazoprevir in Treatment-naïve Chronic Hepatitis C Genotype 1b Patients With Mild Fibrosis: an Open-label, Randomized, Active Control Trial (EGALITE)
Phase of Trial: Phase II
Latest Information Update: 16 Jan 2019
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms EGALITE
- 16 Jan 2019 Last checked against ClinicalTrials.gov record.
- 08 Jan 2019 Status changed from recruiting to completed.
- 13 Nov 2018 Interim results presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases